Re: “Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status” by Yamamoto et al.
Thyroid® · 2024-03 · 34 (3) · 399-400
DOI: 10.1089/thy.2023.0605 ↗Kurz gefasst
Kommentar in der Zeitschrift Thyroid®, online erschienen am 16.01.2024. Verfasst von Jingzhe Xiang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Thyroxine, Thyroid Neoplasms, Carcinoma, Papillary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, China.
Zitieren
APA
Xiang, J., & Zhang, H. (2024). Re: “Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status” by Yamamoto et al. Thyroid®, 34(3), 399-400. https://doi.org/10.1089/thy.2023.0605
Vancouver
Xiang J, Zhang H. Re: “Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status” by Yamamoto et al. Thyroid®. 2024;34(3):399-400. doi:10.1089/thy.2023.0605
BibTeX
@article{Xiang2024,
author = {Xiang, Jingzhe and Zhang, Hao},
title = {Re: “Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status” by Yamamoto et al},
journal = {Thyroid®},
year = {2024},
volume = {34},
number = {3},
pages = {399--400},
doi = {10.1089/thy.2023.0605}
}
EUVIMED